English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Objective.    99m Tc-ethylenedicysteine-glucosamine ( 99m Tc-EC-G) was developed as a potential alternative to  18 F-FDG for cancer imaging. A Phase 2 study was conducted to compare  18 F-FDG PET/CT and  99m Tc-EC-G SPECT/CT in the detection and staging of patients with non-small cell lung cancer (NSCLC). This study was aimed to demonstrate that  99m Tc-EC-G SPECT/CT was not inferior to  18 F-FDG PET/CT in patients with confirmed NSCLC.  Methods.  Seventeen patients with biopsy proven NSCLC were imaged with  99m Tc-EC-G and  18 F-FDG to detect and stage their cancers. Imaging with PET/CT began 45–60 minutes after injection of  18 F-FDG. Imaging with  99m Tc-EC-G began at two hours after injection (for 5 patients) or three hours (for 12 patients). SPECT/CT imaging devices from the three major vendors of SPECT/CT systems were used at 6 participating study sites. The image sets were blinded to all clinical information and interpreted by independent PET and SPECT expert readers at a central independent core laboratory.  Results.  100% concordance between  99m Tc-EC-G and  18 F-FDG for primary lesion detection, lesion location and size, and confidence that the biopsied lesion was malignant. There was 70% agreement between  99m Tc-EC-G and  18 F-FDG for metastatic lesion detection, location and size, and confidence that the suspicious lesions were malignant.  Conclusions.  Evaluation of primary and suspicious metastatic lesions detected by  99m Tc-EC-G and  18 F-FDG on 17 patients resulted in excellent agreement for detection of primary and metastatic lesions. The study results indicated that  99m Tc-EC-G SPECT/CT has the potential to be a clinically viable alternative to  18 F-FDG PET/CT and  99m Tc-EC-G is not inferior to  18 F-FDG PET/CT.

contrast media and molecular imaging/contrast media and molecular imaging

Noninferiority of<sup>99m</sup>Tc-Ethylenedicysteine-Glucosamine as an Alternative Analogue to<sup>18</sup>F-Fluorodeoxyglucose in the Detection and Staging of Non-Small Cell Lung Cancer

Noninferiority of99mTc-Ethylenedicysteine-Glucosamine as an Alternative Analogue to18F-Fluorodeoxyglucose in the Detection and Staging of Non-Small Cell Lung Cancer

Noninferiority of^99mTc-Ethylenedicysteine-Glucosamine as an Alternative Analogue to¹⁸F-Fluorodeoxyglucose in the Detection and Staging of Non-Small Cell Lung Cancer